Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.

Journal of clinical medicine

Yusuf E, Bax HI, Verkaik NJ, van Westreenen M.
PMID: 33806604
J Clin Med. 2021 Mar 04;10(5). doi: 10.3390/jcm10051068.

Infections in the ICU are often caused by Gram-negative bacteria. When these microorganisms are resistant to third-generation cephalosporines (due to extended-spectrum (ESBL) or AmpC beta-lactamases) or to carbapenems (for example carbapenem producing Enterobacteriales (CPE)), the treatment options become limited....

Cite
Yusuf E, Bax HI, Verkaik NJ, et al. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021;10(5)doi: 10.3390/jcm10051068.
Yusuf, E., Bax, H. I., Verkaik, N. J., & van Westreenen, M. (2021). An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. Journal of clinical medicine, 10(5), . https://doi.org/10.3390/jcm10051068
Yusuf, Erlangga, et al. "An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria." Journal of clinical medicine vol. 10,5 (2021). doi: https://doi.org/10.3390/jcm10051068
Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021 Mar 04;10(5). doi: 10.3390/jcm10051068. PMID: 33806604; PMCID: PMC7962006.
Copy Download .nbib Format: NLM
Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Johnston BD, Thuras P, Porter SB, Clabots C, Johnson JR.
PMID: 33893571
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2069-2075. doi: 10.1007/s10096-021-04256-9. Epub 2021 Apr 23.

Extended-spectrum cephalosporin-resistant Escherichia coli (ESCREC) are a growing threat. Leading ESCREC lineages include sequence type ST131, especially its (bla

Cite
Johnston BD, Thuras P, Porter SB, et al. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. Eur J Clin Microbiol Infect Dis. 2021;40(10):2069-2075doi: 10.1007/s10096-021-04256-9.
Johnston, B. D., Thuras, P., Porter, S. B., Clabots, C., & Johnson, J. R. (2021). Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 40(10), 2069-2075. https://doi.org/10.1007/s10096-021-04256-9
Johnston, Brian D, et al. "Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology vol. 40,10 (2021): 2069-2075. doi: https://doi.org/10.1007/s10096-021-04256-9
Johnston BD, Thuras P, Porter SB, Clabots C, Johnson JR. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2069-2075. doi: 10.1007/s10096-021-04256-9. Epub 2021 Apr 23. PMID: 33893571; PMCID: PMC8449799.
Copy Download .nbib Format: NLM
Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.

International journal of antimicrobial agents

Arca-Suárez J, Rodiño-Janeiro BK, Pérez A, Guijarro-Sánchez P, Vázquez-Ucha JC, Cruz F, Gómez-Garrido J, Alioto TS, Álvarez-Tejado M, Gut M, Gut I, Oviaño M, Beceiro A, Bou G.
PMID: 34688835
Int J Antimicrob Agents. 2022 Jan;59(1):106456. doi: 10.1016/j.ijantimicag.2021.106456. Epub 2021 Oct 21.

The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support...

Cite
Arca-Suárez J, Rodiño-Janeiro BK, Pérez A, et al. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. Int J Antimicrob Agents. 2021;59(1):106456doi: 10.1016/j.ijantimicag.2021.106456.
Arca-Suárez, J., Rodiño-Janeiro, B. K., Pérez, A., Guijarro-Sánchez, P., Vázquez-Ucha, J. C., Cruz, F., Gómez-Garrido, J., Alioto, T. S., Álvarez-Tejado, M., Gut, M., Gut, I., Oviaño, M., Beceiro, A., Bou, G. (2022). Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. International journal of antimicrobial agents, 59(1), 106456. https://doi.org/10.1016/j.ijantimicag.2021.106456
Arca-Suárez, Jorge, et al. "Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing." International journal of antimicrobial agents vol. 59,1 (2022): 106456. doi: https://doi.org/10.1016/j.ijantimicag.2021.106456
Arca-Suárez J, Rodiño-Janeiro BK, Pérez A, Guijarro-Sánchez P, Vázquez-Ucha JC, Cruz F, Gómez-Garrido J, Alioto TS, Álvarez-Tejado M, Gut M, Gut I, Oviaño M, Beceiro A, Bou G. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. Int J Antimicrob Agents. 2022 Jan;59(1):106456. doi: 10.1016/j.ijantimicag.2021.106456. Epub 2021 Oct 21. PMID: 34688835.
Copy Download .nbib Format: NLM
Shifting Gears: The Future of Polymyxin Antibiotics.

Antibiotics (Basel, Switzerland)

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.
PMID: 31013818
Antibiotics (Basel). 2019 Apr 12;8(2). doi: 10.3390/antibiotics8020042.

The manuscripts contained in this special edition of Antibiotics represent a current review of the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which was held in Madrid, Spain, April 25 to 26, 2018. The role...

Cite
Lenhard JR, Bulman ZP, Tsuji BT, et al. Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics (Basel). 2019;8(2)doi: 10.3390/antibiotics8020042.
Lenhard, J. R., Bulman, Z. P., Tsuji, B. T., & Kaye, K. S. (2019). Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics (Basel, Switzerland), 8(2), . https://doi.org/10.3390/antibiotics8020042
Lenhard, Justin R, et al. "Shifting Gears: The Future of Polymyxin Antibiotics." Antibiotics (Basel, Switzerland) vol. 8,2 (2019). doi: https://doi.org/10.3390/antibiotics8020042
Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS. Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics (Basel). 2019 Apr 12;8(2). doi: 10.3390/antibiotics8020042. PMID: 31013818; PMCID: PMC6628003.
Copy Download .nbib Format: NLM
Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Antimicrobial agents and chemotherapy

Clancy CJ, Nguyen MH.
PMID: 31591123
Antimicrob Agents Chemother. 2019 Oct 07; doi: 10.1128/AAC.01733-19. Epub 2019 Oct 07.

New antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) improve outcomes of CRE-infected patients. However, companies developing these drugs have faced financial difficulties. Sales of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin in the United States (US) totaled $101 million from February 2018-January...

Cite
Clancy CJ, Nguyen MH. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01733-19.
Clancy, C. J., & Nguyen, M. H. (2019). Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae. Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01733-19
Clancy, Cornelius J, and Nguyen, M Hong. "Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01733-19
Clancy CJ, Nguyen MH. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Oct 07; doi: 10.1128/AAC.01733-19. Epub 2019 Oct 07. PMID: 31591123; PMCID: PMC6879237.
Copy Download .nbib Format: NLM
Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Current infectious disease reports

Lasko MJ, Nicolau DP.
PMID: 32034524
Curr Infect Dis Rep. 2020 Feb 07;22(3):6. doi: 10.1007/s11908-020-0716-3.

PURPOSE OF REVIEW: Gram-negative resistance is a growing concern globally. Enterobacterales, formerly Enterobacteriaceae, have developed resistance mechanisms to carbapenems that leave very few antimicrobial options in the clinician's armamentarium.RECENT FINDINGS: New antimicrobials like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and plazomicin...

Cite
Lasko MJ, Nicolau DP. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Curr Infect Dis Rep. 2020;22(3):6doi: 10.1007/s11908-020-0716-3.
Lasko, M. J., & Nicolau, D. P. (2020). Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Current infectious disease reports, 22(3), 6. https://doi.org/10.1007/s11908-020-0716-3
Lasko, Maxwell J, and Nicolau, David P. "Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology." Current infectious disease reports vol. 22,3 (2020): 6. doi: https://doi.org/10.1007/s11908-020-0716-3
Lasko MJ, Nicolau DP. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Curr Infect Dis Rep. 2020 Feb 07;22(3):6. doi: 10.1007/s11908-020-0716-3. PMID: 32034524; PMCID: PMC7223591.
Copy Download .nbib Format: NLM
Treatment Options for Colistin Resistant .

Journal of clinical medicine

Petrosillo N, Taglietti F, Granata G.
PMID: 31261755
J Clin Med. 2019 Jun 28;8(7). doi: 10.3390/jcm8070934.

Multidrug-resistant (MDR)

Cite
Petrosillo N, Taglietti F, Granata G. Treatment Options for Colistin Resistant . J Clin Med. 2019;8(7)doi: 10.3390/jcm8070934.
Petrosillo, N., Taglietti, F., & Granata, G. (2019). Treatment Options for Colistin Resistant . Journal of clinical medicine, 8(7), . https://doi.org/10.3390/jcm8070934
Petrosillo, Nicola, et al. "Treatment Options for Colistin Resistant ." Journal of clinical medicine vol. 8,7 (2019). doi: https://doi.org/10.3390/jcm8070934
Petrosillo N, Taglietti F, Granata G. Treatment Options for Colistin Resistant . J Clin Med. 2019 Jun 28;8(7). doi: 10.3390/jcm8070934. PMID: 31261755; PMCID: PMC6678465.
Copy Download .nbib Format: NLM
[No title available]

Aktuelle Urologie

[No authors listed]
PMID: 31398750
Aktuelle Urol. 2019 Aug;50(4):338-340. doi: 10.1055/a-0875-0712. Epub 2019 Aug 09.

No abstract available.

Cite
Komplizierter Harnwegsinfekt: Plazomicin versus Meropenem. . Aktuelle Urol. 2019;50(4):338-340doi: 10.1055/a-0875-0712.
(2019). Komplizierter Harnwegsinfekt: Plazomicin versus Meropenem. . Aktuelle Urologie, 50(4), 338-340. https://doi.org/10.1055/a-0875-0712
"Komplizierter Harnwegsinfekt: Plazomicin versus Meropenem." . Aktuelle Urologie vol. 50,4 (2019): 338-340. doi: https://doi.org/10.1055/a-0875-0712
Komplizierter Harnwegsinfekt: Plazomicin versus Meropenem. . Aktuelle Urol. 2019 Aug;50(4):338-340. doi: 10.1055/a-0875-0712. Epub 2019 Aug 09. German. PMID: 31398750.
Copy Download .nbib Format: NLM
Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach.

Journal of biomolecular structure & dynamics

Botelho FD, Santos MC, Gonçalves AS, França TCC, LaPlante SR, de Almeida JSFD.
PMID: 33410376
J Biomol Struct Dyn. 2021 Jan 07;1-11. doi: 10.1080/07391102.2020.1870154. Epub 2021 Jan 07.

Ricin is a potent cytotoxin with no available antidote. Its catalytic subunit, RTA, damages the ribosomal RNA (rRNA) of eukaryotic cells, preventing protein synthesis and eventually leading to cell death. The combination between easiness of obtention and high toxicity...

Cite
Botelho FD, Santos MC, Gonçalves AS, et al. Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach. J Biomol Struct Dyn. 2021;1-11doi: 10.1080/07391102.2020.1870154.
Botelho, F. D., Santos, M. C., Gonçalves, A. S., França, T. C. C., LaPlante, S. R., & de Almeida, J. S. F. D. (2021). Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach. Journal of biomolecular structure & dynamics, 1-11. https://doi.org/10.1080/07391102.2020.1870154
Botelho, Fernanda D, et al. "Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach." Journal of biomolecular structure & dynamics vol. (2021): 1-11. doi: https://doi.org/10.1080/07391102.2020.1870154
Botelho FD, Santos MC, Gonçalves AS, França TCC, LaPlante SR, de Almeida JSFD. Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach. J Biomol Struct Dyn. 2021 Jan 07;1-11. doi: 10.1080/07391102.2020.1870154. Epub 2021 Jan 07. PMID: 33410376.
Copy Download .nbib Format: NLM
Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains.

Antibiotics (Basel, Switzerland)

Valderrama MJ, Alfaro M, Rodríguez-Avial I, Baos E, Rodríguez-Avial C, Culebras E.
PMID: 32784878
Antibiotics (Basel). 2020 Aug 09;9(8). doi: 10.3390/antibiotics9080496.

Linezolid is a synthetic oxazolydinone active against multi-resistant Gram-positive cocci that inhibits proteins synthesis by interacting with the 50S ribosomal subunit. Although linezolid-resistant strains are infrequent, several outbreaks have been recently described, associated with prolonged treatment with the antibiotic....

Cite
Valderrama MJ, Alfaro M, Rodríguez-Avial I, et al. Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains. Antibiotics (Basel). 2020;9(8)doi: 10.3390/antibiotics9080496.
Valderrama, M. J., Alfaro, M., Rodríguez-Avial, I., Baos, E., Rodríguez-Avial, C., & Culebras, E. (2020). Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains. Antibiotics (Basel, Switzerland), 9(8), . https://doi.org/10.3390/antibiotics9080496
Valderrama, María-José, et al. "Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains." Antibiotics (Basel, Switzerland) vol. 9,8 (2020). doi: https://doi.org/10.3390/antibiotics9080496
Valderrama MJ, Alfaro M, Rodríguez-Avial I, Baos E, Rodríguez-Avial C, Culebras E. Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains. Antibiotics (Basel). 2020 Aug 09;9(8). doi: 10.3390/antibiotics9080496. PMID: 32784878; PMCID: PMC7460281.
Copy Download .nbib Format: NLM
Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.

BMC infectious diseases

Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M.
PMID: 30845925
BMC Infect Dis. 2019 Mar 07;19(1):230. doi: 10.1186/s12879-019-3854-1.

Following publication of the original article [1].

Cite
Galani I, Nafplioti K, Adamou P, et al. Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019;19(1):230doi: 10.1186/s12879-019-3854-1.
Galani, I., Nafplioti, K., Adamou, P., Karaiskos, I., Giamarellou, H., Souli, M. (2019). Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC infectious diseases, 19(1), 230. https://doi.org/10.1186/s12879-019-3854-1
Galani, Irene, et al. "Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance." BMC infectious diseases vol. 19,1 (2019): 230. doi: https://doi.org/10.1186/s12879-019-3854-1
Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M. Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019 Mar 07;19(1):230. doi: 10.1186/s12879-019-3854-1. PMID: 30845925; PMCID: PMC6404269.
Copy Download .nbib Format: NLM
Radiolabeling, characterization, and preclinical evaluation of plazomicin: A potential tracer for bacterial infection.

Chemical biology & drug design

El-Kawy OA, Abdelaziz G, Abdel-Razek AS.
PMID: 34923759
Chem Biol Drug Des. 2021 Dec 19; doi: 10.1111/cbdd.14007. Epub 2021 Dec 19.

In this study,

Cite
El-Kawy OA, Abdelaziz G, Abdel-Razek AS. Radiolabeling, characterization, and preclinical evaluation of plazomicin: A potential tracer for bacterial infection. Chem Biol Drug Des. 2021;doi: 10.1111/cbdd.14007.
El-Kawy, O. A., Abdelaziz, G., & Abdel-Razek, A. S. (2021). Radiolabeling, characterization, and preclinical evaluation of plazomicin: A potential tracer for bacterial infection. Chemical biology & drug design, . https://doi.org/10.1111/cbdd.14007
El-Kawy, O A, et al. "Radiolabeling, characterization, and preclinical evaluation of plazomicin: A potential tracer for bacterial infection." Chemical biology & drug design vol. (2021). doi: https://doi.org/10.1111/cbdd.14007
El-Kawy OA, Abdelaziz G, Abdel-Razek AS. Radiolabeling, characterization, and preclinical evaluation of plazomicin: A potential tracer for bacterial infection. Chem Biol Drug Des. 2021 Dec 19; doi: 10.1111/cbdd.14007. Epub 2021 Dec 19. PMID: 34923759.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries